- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Turing CEO Shkreli Arrested for Fraud
Martin Shkreli, Turing CEO, was arrested on fraud related to his time as a hedge fund manager, not his recent price gouging of Daraprim.
Martin Shkreli, famous for hiking the price of Daraprim by 5000% after purchasing the 62-year-old drug, was arrested Thursday morning. The investigation is related to his time as a hedge fund manager, not his widely criticized price gouging, reported The New York Times.
Shkreli, the CEO of Turing Pharmaceuticals, became a household name after he increased the price of a life-saving pill from $13.50 to $750 overnight. However, it is for what he did when he was in charge of the biopharmaceutical company Retrophin that the federal case rests on.
Retrophin has also filed a civil lawsuit against Shkreli for the misuse of company funds and for engineering numerous transactions between the company and MSMB Capital Management, Shkreli’s own hedge fund, reported Bloomberg Business.
Two weeks earlier, Shkreli appeared at the Forbes Healthcare Summit and acknowledged that the duty he had to shareholders—to maximize profits—could make him a target for prosecutors.
More on this story as it develops.
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
May 22nd 2025FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Read More
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
May 17th 2025The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).
Read More
